Search - tctmd.com

Displaying 1 - 20 of 115

Sort: Relevancy | Date

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

FDA Perspectives on Short DAPT IDE Trials

Presenter: Michael C. John, Gregg W. Stone, Andrew Farb

November 01, 2016

Presentation TCT 2016

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger

November 01, 2016

Presentation TCT 2016

2016 DAPT Update: Evidence and Guidelines

Presenter: Sripal Bangalore, George D. Dangas, Adnan K. Chhatriwalla

November 01, 2016

Presentation TCT 2016

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Presenter: David J. Cohen, Ajay J. Kirtane, Alan C. Yeung, Gennaro Giustino

November 01, 2016

Presentation TCT 2016

Deciding on the Duration of DAPT

Presenter: George D. Dangas, Debabrata Mukherjee, Neal S. Kleiman

November 01, 2016

Presentation TCT 2016

Case Presentation: Difficult DAPT Duration Decision After PCI

Presenter: Alejandro Cherro, Anibal A. Damonte, Alfredo E. Rodriguez, Marcelo Bettinotti

October 31, 2016

Presentation TCT 2016

Duration of DAPT Therapy With Contemporary DES (Including BVS)

Presenter: Alejandro Cherro, Anibal A. Damonte, Alfredo E. Rodriguez, Gustavo A Samaja

October 31, 2016

Presentation TCT 2016

Risk Scores: Development, Validation, Utility, and Limitations (With Case Studies: Framingham, TIMI/GRACE, CHADS/HASBLED, DAPT, and Others)

Presenter: Scott Berry, Stuart J. Pocock, Ajay J. Kirtane

October 30, 2016

Presentation TCT 2016

From ARCTIC to ANTARCTICA: Is the Concept of Tailored Antiplatelet Therapy Finished

Presenter: John A. Bittl, Daniel I. Simon, Eric Van Belle

October 30, 2016

Presentation TCT 2016

Do All Patients With ACS Need 1 Year (Or Longer) DAPT After PCI?

Presenter: John A. Bittl, Daniel I. Simon, Tullio Palmerini

October 30, 2016

Presentation TCT 2016

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

Presenter: John A. Bittl, Daniel I. Simon, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson

October 30, 2016

Presentation TCT 2016

Optimal DAPT Duration After Complex or Complicated PCI: A Pooled Analysis

Presenter: John A. Bittl, Daniel I. Simon, Gennaro Giustino

October 30, 2016

Presentation TCT 2016

Individualizing Care: Which Patients Might Benefit From Prolonged DAPT? Who Might Be Harmed?

Presenter: John A. Bittl, Daniel I. Simon, Robert W. Yeh

October 30, 2016

Presentation TCT 2016

Strengths and Limitations of Risk Scores to Identify Patients for Long vs Short DAPT

Presenter: John A. Bittl, Daniel I. Simon, Roxana Mehran

October 30, 2016

Presentation TCT 2016

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Presenter: John A. Bittl, Daniel I. Simon, Glenn N. Levine

October 30, 2016

Presentation TCT 2016

Summary and Rationale For the ESC Guidelines on DAPT Duration After PCI

Presenter: John A. Bittl, Daniel I. Simon, Freek W.A. Verheugt

October 30, 2016

Presentation TCT 2016

Start With the Debate - DAPT Duration With Contemporary DES: Short DAPT For Most!

Presenter: John A. Bittl, Daniel I. Simon, Salvatore Cassese

October 30, 2016

Presentation TCT 2016

Start With the Debate - DAPT Duration With Contemporary DES: Prolonged DAPT For Most!

Presenter: John A. Bittl, Daniel I. Simon, Laura Mauri

October 30, 2016

Advertisement

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

FDA Perspectives on Short DAPT IDE Trials

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

2016 DAPT Update: Evidence and Guidelines

Opening Salvo: I Don't Believe That DAPT Should Be Continued Beyond 12 Months in Most Patients Undergoing PCI!

Deciding on the Duration of DAPT

Case Presentation: Difficult DAPT Duration Decision After PCI

Duration of DAPT Therapy With Contemporary DES (Including BVS)

Risk Scores: Development, Validation, Utility, and Limitations (With Case Studies: Framingham, TIMI/GRACE, CHADS/HASBLED, DAPT, and Others)

From ARCTIC to ANTARCTICA: Is the Concept of Tailored Antiplatelet Therapy Finished

Do All Patients With ACS Need 1 Year (Or Longer) DAPT After PCI?

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Optimal DAPT Duration After Complex or Complicated PCI: A Pooled Analysis

Individualizing Care: Which Patients Might Benefit From Prolonged DAPT? Who Might Be Harmed?

Strengths and Limitations of Risk Scores to Identify Patients for Long vs Short DAPT

Summary and Rationale For the ACC-AHA Guidelines on DAPT Duration After PCI

Summary and Rationale For the ESC Guidelines on DAPT Duration After PCI

Start With the Debate - DAPT Duration With Contemporary DES: Short DAPT For Most!

Start With the Debate - DAPT Duration With Contemporary DES: Prolonged DAPT For Most!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content